BiotechTube

AMG 139

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Psoriasis

Conditions

Psoriasis

Trial Timeline

Apr 11, 2010 → Jul 26, 2011

NCT ID
NCT01094093

About AMG 139

AMG 139 is a phase 1 stage product being developed by AstraZeneca for Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT01094093. Target conditions include Psoriasis.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (2)

NCT IDPhaseStatus
NCT01258205Phase 1Completed
NCT01094093Phase 1Completed

Competing Products

20 competing products in Psoriasis

See all competitors
ProductCompanyStageHype Score
Ixekizumab + PlaceboEli LillyPhase 2
52
VTX958 Dose A + VTX958 Dose B + VTX958 Dose C + VTX958 Dose D + PlaceboVentyx BiosciencesPhase 2
47
LY2525623 Intravenous + LY2525623 Subcutaneous + Placebo Intravenous + Placebo SubcutaneousEli LillyPhase 2
52
IxekizumabEli LillyPhase 3
77
80 mg Ixekizumab Dosing Regimens 1, 2, and 3 + PlaceboEli LillyPhase 3
77
Placebo + BaricitinibEli LillyPhase 2
52
CT-P43 + StelaraCelltrionPhase 3
77
CT-P17 + EU-approved HumiraCelltrionPhase 3
77
CT-P55 + EU-approved CosentyxCelltrionPhase 3
77
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
85
alefaceptAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77
alefaceptAstellas PharmaPhase 3
77
peficitinib + PlaceboAstellas PharmaPhase 2
52
AlefaceptAstellas PharmaPhase 3
77
Amevive exposureAstellas PharmaPre-clinical
23
alefacept + placeboAstellas PharmaPhase 3
77
alefaceptAstellas PharmaApproved
85
ASKP1240 + PlaceboAstellas PharmaPhase 2
52
Tacrolimus CreamAstellas PharmaPhase 3
77

Other Products from AstraZeneca

QuetiapineApproved
85
Dapagliflozin 5 mg + Placebo tabletApproved
85
QuetiapineApproved
85
Ticagrelor + ClopidogrelApproved
85
DurvalumabApproved
85